Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease.

Hiller, Benjamin M; Marmion, David J; Thompson, Cayla A; Elliott, Nathaniel A; Federoff, Howard; Brundin, Patrik; Mattis, Virginia B; McMahon, Christopher W; Kordower, Jeffrey H

Hiller, Benjamin M; Marmion, David J; Thompson, Cayla A; Elliott, Nathaniel A; Federoff, Howard; Brundin, Patrik; Mattis, Virginia B; McMahon, Christopher W; Kordower, Jeffrey H.

Afiliação

Hiller BM; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Marmion DJ; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Thompson CA; Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.
Elliott NA; FUJIFILM Cellular Dynamics Inc., Madison, WI, USA.
Federoff H; FUJIFILM Cellular Dynamics Inc., Madison, WI, USA.
Brundin P; Brooklyn ImmunoTherapeutics, Brooklyn, NY, USA.
Mattis VB; Parkinson's Disease Center, Department for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.
McMahon CW; FUJIFILM Cellular Dynamics Inc., Madison, WI, USA.
Kordower JH; FUJIFILM Cellular Dynamics Inc., Madison, WI, USA.

NPJ Regen Med ; 7(1): 24, 2022 Apr 21.

Article em En | MEDLINE | ID: mdl-35449132

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: NPJ Regen Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google